Advertisement
Journal Home
Search for

Volume 81, Issue 6, Pages 481-486 (June 2010)


View previous. 7 of 21 View next.

Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine system

Oskari Heikinheimoa, Pirjo Inkib, Michael Kunzb, Sule Parmhedc, Anna-Maija Anttilad, Sven-Eric Olssone, Ritva Hurskainenf, Kristina Gemzell-DanielssongCorresponding Author Informationemail address

Received 7 July 2009; received in revised form 16 November 2009; accepted 26 January 2010. published online 02 March 2010.

Abstract 

Background

Misoprostol has been studied intensively to produce cervical dilatation. To date, no studies have evaluated the effectiveness, safety or acceptability of this treatment for repeat intrauterine device insertions.

Study Design

This study was a randomized, double-blind, placebo-controlled trial on the consecutive use of the levonorgestrel-releasing intrauterine system (LNG-IUS). Women who had used their first LNG-IUS for 4 years and 3 to 9 months and opted for an immediate replacement with a second LNG-IUS received a single sublingual dose of 400 mcg misoprostol or placebo 3 h prior to the LNG-IUS insertion.

Results

The proportion of easy insertions as judged by the investigator was 93% (40/43) in subjects randomized to misoprostol and 91% (42/46) in the placebo group (p=1.0 for the difference of proportions). No or mild pain at insertion was reported by 37% and 35% of subjects in the misoprostol and placebo groups, respectively. However, adverse events related to the study drug were more common in the misoprostol group.

Conclusion

Sublingual misoprostol did not have a significant effect on the ease of insertion in subjects having a repeat insertion of the LNG-IUS.

a Department of Obstetrics and Gynecology, Helsinki University Central Hospital, 00029-HUS Helsinki, Finland

b Bayer Schering Pharma AG, DE-13342 Berlin, Germany

c Sesam-Södersjukhuset, SE-11883 Stockholm, Sweden

d Suomen Terveystalo, FI-33100 Tampere, Finland

e Prima Liv KK, DS AB Danderyds sjukhus AB, SE-18288 Stockholm, Sweden

f Hyvinkää Hospital, FI-05800 Hyvinkää, Finland

g Department of Woman and Child Health, Division of Obstetrics and Gynecology, Karolinska Institutet/University Hospital SE-17176 Stockholm, Sweden

Corresponding Author InformationCorresponding author. Tel.: +46 8 51772128; fax: +46 851774314.

PII: S0010-7824(10)00040-5

doi:10.1016/j.contraception.2010.01.020


View previous. 7 of 21 View next.

Advertisement